A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Neoplasms

Interventions

DRUG

Aneustat (OMN54)

100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID

Trial Locations (1)

BC Cancer Agency-Vancouver Centre, Vancouver